RB1 and cancer: The molecular intervention analysis showed that the combinatory inhibition of oncogenic molecules e.g. PDK1, AKT, and MDM2 or the activation of P53, RB and CDH1 reduces the proliferation and increases quiescent phenotypes since the targeted drug associations blocked cancer pathways at different regions [112].